Thermo Fisher Scientific (NYSE: TMO)Share Price and News
Overview of Thermo Fisher Scientific (NYSE:TMO)
Thermo Fisher Scientific operates as a leading global healthcare company. If you name something to do with healthcare, it is more likelier than not that Thermo Fisher does that.
This company (based on the outskirts of Boston, Massachusetts) makes, supplies and provides lab equipment, pharmaceutical drugs, consumables for medical devices and medical software just to name a few. But it is lab products and biopharmaceutical services that is its biggest revenue generator (making roughly half of its revenue).
The company's global footprint and diversified product offering position Thermo Fisher as a crucial player in advancing life sciences and healthcare worldwide. It has 125,000 employees, 7,500 of which are dedicated to R&D. Today, Thermo Fisher is widely regarded as a leader in scientific infrastructure, helping support everything from academic research to the development and production of new medicines.
Thermo Fisher's Company History
Thermo Fisher's journey began with Thermo Electron Corporation in 1956, expanding through a series of strategic acquisitions and mergers. This was the company that introduced single-use bio-reactors and the first automated DNA analyser.
Nonetheless, Thermo Electron was a modest company up until the 2006 merger Fisher Scientific. Prior to that, it was only a US$2bn revenue per year company, but this deal created a powerhouse in scientific equipment and consumables, adopting the Thermo Fisher Scientific name.
Over the years, the company has continued to grow through acquisitions, including the significant purchase of Life Technologies, completed in early 2014 after being announced in 2013, which expanded its capabilities in genetic analysis.
More recently, Thermo Fisher acquired the clinical diagnostics firm PPD in 2021, bolstering its contract research services. These milestones reflect Thermo Fisher's continuous evolution from a laboratory supplier to a comprehensive provider of scientific and clinical solutions.
Future Outlook of Thermo Fisher Scientific (NYSE: TMO)
As demand for advanced diagnostics, genomics and biologic drug development continues to rise globally, the company is well positioned to benefit from increased investment in life sciences infrastructure.
The company has continued investing heavily in acquisitions and capacity expansion to strengthen its role across the pharmaceutical development pipeline. Recent deals and investments have focused particularly on bioprocessing, clinical research services and advanced laboratory technologies, which are key growth areas in the global healthcare industry. Management has also emphasised innovation and productivity improvements through its internal operational framework, which aims to improve efficiency while supporting long-term margin expansion.
For 2026, Thermo Fisher has provided specific financial guidance indicating continued growth. The company expects revenue between approximately $46.3 billion and $47.2 billion, representing roughly 4%–6% reported growth compared with 2025, with 3%–4% organic revenue growth expected. The company has also guided adjusted earnings per share of about $24.22 to $24.80, implying 6%–8% EPS growth year-over-year, alongside an expected improvement in operating margins.
Additional upside could come from acquisitions. For example, Thermo Fisher has agreed to acquire clinical trial technology company Clario, which management expects could contribute incremental earnings once the deal closes.
Is Thermo Fisher a Good Stock to Buy?
Thermo Fisher Scientific is often viewed as one of the highest-quality companies in the life sciences sector. The company benefits from a diversified business model that includes laboratory equipment, consumables, diagnostics and pharmaceutical development services. This diversification allows it to generate revenue from both large capital equipment sales and recurring laboratory supplies.
One of the main strengths of Thermo Fisher is its position within the global research and drug development ecosystem. Pharmaceutical companies, biotechnology firms and academic laboratories rely heavily on its instruments, reagents and services. As global healthcare innovation accelerates, this creates long-term demand for the company’s products and infrastructure.
Thermo Fisher has also demonstrated a strong history of growth through acquisitions. By integrating complementary businesses into its platform, the company has expanded its capabilities and deepened relationships with pharmaceutical customers. These acquisitions have played a key role in building its leadership across bioprocessing and clinical research services.
However, investors should also consider several risks. Demand for scientific instruments can fluctuate with government research funding and biotech investment cycles. Economic uncertainty or reduced research spending can temporarily slow growth in some of the company’s end markets.
Valuation is another consideration. Thermo Fisher often trades at a premium compared with many industrial and healthcare companies due to its consistent growth and strong market position.
Overall, Thermo Fisher Scientific may appeal to long-term investors seeking exposure to the growth of biotechnology, pharmaceuticals and scientific research infrastructure. While short-term performance can be influenced by research funding cycles and macroeconomic conditions, the company’s scale, diversification and innovation pipeline position it as a leading player in the life sciences industry.
Our Stock Analysis
Thermo Fisher (NYSE:TMO): A classic blue-chip health stock for the rest of the 2020s
Capped at over US$180bn, Thermo Fisher (NYSE:TMO) is a classic blue-chip healthcare stock. It has not escaped an impact from…
Here are 5 US stocks for Australian investors other than the Magnificent Seven!
When thinking about US stocks for Australian investors, it is easy to just name the Magnificent Seven and be done…
Frequently Asked Questions
Thermo Fisher currently offers a dividend yield of approximately 0.3%, with a track record of regular dividend growth reflecting its strong cash flow and earnings stability.